AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma

(MedPage Today) -- At the recent American Society of Hematology (ASH) annual meeting, data from a phase I trial of AZD0486--a novel CD19xCD3 bispecific T-cell engager--showed high response rates and encouraging safety in relapsed/refractory...